Investment In HIV/AIDS Vaccine R&D Must Be Scaled Up

Global Health Technology Coalition’s “Breakthroughs”: Four reasons now is the time to ramp up investment in HIV/AIDS vaccine R&D
Kat Kelley, GHTC’s senior program assistant, reports from a recent briefing on Capitol Hill that “convened leaders in the field to discuss the state of HIV/AIDS vaccine research and development (R&D). … [T]he discussion illustrated four key reasons why now is the time to ramp up — rather than scale down — investment in HIV/AIDS vaccine R&D. … We are closer than ever to developing an HIV/AIDS vaccine … We cannot eradicate HIV/AIDS without a vaccine … Investments in HIV/AIDS vaccine R&D are producing broader impacts on global health … A vaccine for HIV/AIDS would have enormous financial benefits” (5/22).